Kenvue Inc. (NYSE:KVUE) Shares Sold by Palouse Capital Management Inc.

Palouse Capital Management Inc. reduced its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 87,090 shares of the company’s stock after selling 3,467 shares during the quarter. Palouse Capital Management Inc.’s holdings in Kenvue were worth $1,875,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Empirical Finance LLC acquired a new stake in shares of Kenvue in the 3rd quarter valued at about $336,000. UniSuper Management Pty Ltd acquired a new stake in shares of Kenvue in the 3rd quarter valued at about $35,544,000. Howland Capital Management LLC acquired a new stake in shares of Kenvue in the 3rd quarter valued at about $7,764,000. Citizens Business Bank acquired a new stake in shares of Kenvue in the 3rd quarter valued at about $2,507,000. Finally, Fifth Third Bancorp boosted its position in shares of Kenvue by 35.3% in the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock valued at $5,976,000 after purchasing an additional 72,435 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Sanford C. Bernstein began coverage on Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price for the company. William Blair began coverage on Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating for the company. The Goldman Sachs Group began coverage on Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. decreased their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. Finally, Royal Bank of Canada decreased their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $24.85.

Kenvue Stock Performance

Shares of KVUE stock remained flat at $19.58 during trading hours on Friday. The stock had a trading volume of 9,504,809 shares, compared to its average volume of 16,610,629. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80. The business’s 50-day simple moving average is $19.83 and its 200 day simple moving average is $20.16. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.03. The firm had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. On average, equities analysts forecast that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 annualized dividend and a yield of 4.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.